Form 4 holding
Director
Savara Inc
- Security class
- Common Stock
- Shares / value
- 2,533,642
- Estimated value
- $15,356,404
- Report date
- 19 Dec 2025
- Price
- $6.06
- Ownership
- Direct
David A. Ramsay
Insider Reports History
- Reporting-owner location
- San Diego, CA
- Latest reporting-owner signature
-
/s/ James R. Oehler, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for David A. Ramsay
Form 4 holding
EVP, PRESIDENT, DRUG DELIVERY
HALOZYME THERAPEUTICS, INC.
- Security class
- Common Stock
- Shares / value
- 4,592
- Estimated value
- $296,780
- Report date
- 30 Jun 2026
- Price
- $64.63
- Ownership
- Direct
Form 4 holding
EVP, PRESIDENT, DRUG DELIVERY
HALOZYME THERAPEUTICS, INC.
- Security class
- Option to Purchase Common Stock
- Shares / value
- 39,823
- Estimated value
- Report date
- 01 Jul 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
EVP, PRESIDENT, DRUG DELIVERY
HALOZYME THERAPEUTICS, INC.
- Security class
- Restricted Stock Units
- Shares / value
- 16,232
- Estimated value
- Report date
- 01 Jul 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
LA JOLLA PHARMACEUTICAL CO
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 22 Aug 2022
- Price
- $6.23
- Ownership
- Direct
Form 4 holding
Director
LA JOLLA PHARMACEUTICAL CO
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 22 Aug 2022
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by David A. Ramsay
4
HALO
HALOZYME THERAPEUTICS, INC.
- Report period
- 30 Jun 2026
- Transactions
- 5
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2026, 16:45
- Role
- EVP, PRESIDENT, DRUG DELIVERY
- Next action
- Open filing details
4
HALO
HALOZYME THERAPEUTICS, INC.
- Report period
- 01 Apr 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Apr 2026, 18:29
- Role
- Interim CFO
- Next action
- Open filing details
3
HALO
HALOZYME THERAPEUTICS, INC.
- Report period
- 23 Mar 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 23 Mar 2026, 18:35
- Role
- Interim CFO
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 19 Dec 2025
- Transactions
- 1
- Transaction value
- -$121,220
- Accepted by SEC
- 19 Dec 2025, 17:00
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 09 Dec 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Dec 2025, 17:45
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 31 Mar 2025
- Transactions
- 1
- Transaction value
- +$416,250
- Accepted by SEC
- 01 Apr 2025, 07:00
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 12 Dec 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 Dec 2024, 17:40
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 18 Nov 2024
- Transactions
- 1
- Transaction value
- +$287,600
- Accepted by SEC
- 18 Nov 2024, 12:33
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 14 Dec 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Dec 2023, 17:37
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 24 May 2023
- Transactions
- 3
- Transaction value
- +$258,529
- Accepted by SEC
- 26 May 2023, 11:31
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 29 Dec 2022
- Transactions
- 2
- Transaction value
- +$55,586
- Accepted by SEC
- 03 Jan 2023, 11:41
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 23 Dec 2022
- Transactions
- 2
- Transaction value
- +$27,588
- Accepted by SEC
- 28 Dec 2022, 15:40
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 20 Dec 2022
- Transactions
- 2
- Transaction value
- +$66,434
- Accepted by SEC
- 22 Dec 2022, 14:19
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 16 Dec 2022
- Transactions
- 3
- Transaction value
- +$82,105
- Accepted by SEC
- 20 Dec 2022, 12:29
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 13 Dec 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Dec 2022, 15:10
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 22 Nov 2022
- Transactions
- 2
- Transaction value
- +$28,652
- Accepted by SEC
- 25 Nov 2022, 07:30
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 17 Nov 2022
- Transactions
- 3
- Transaction value
- +$68,441
- Accepted by SEC
- 21 Nov 2022, 15:39
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 23 Sep 2022
- Transactions
- 3
- Transaction value
- +$187,093
- Accepted by SEC
- 27 Sep 2022, 12:49
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 16 Sep 2022
- Transactions
- 3
- Transaction value
- +$11,562
- Accepted by SEC
- 20 Sep 2022, 16:08
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 06 Sep 2022
- Transactions
- 3
- Transaction value
- +$44,722
- Accepted by SEC
- 08 Sep 2022, 15:37
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 30 Aug 2022
- Transactions
- 3
- Transaction value
- +$141,932
- Accepted by SEC
- 01 Sep 2022, 16:37
- Role
- Director
- Next action
- Open filing details
4
LA JOLLA PHARMACEUTICAL CO
- Report period
- 22 Aug 2022
- Transactions
- 5
- Transaction value
- -$623,000
- Accepted by SEC
- 24 Aug 2022, 20:22
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 17 Jun 2022
- Transactions
- 3
- Transaction value
- +$138,380
- Accepted by SEC
- 22 Jun 2022, 13:23
- Role
- Director
- Next action
- Open filing details
4
LA JOLLA PHARMACEUTICAL CO
- Report period
- 12 Jan 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Jan 2022, 20:00
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 29 Dec 2021
- Transactions
- 2
- Transaction value
- +$64,035
- Accepted by SEC
- 30 Dec 2021, 13:00
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 15 Dec 2021
- Transactions
- 2
- Transaction value
- +$44,485
- Accepted by SEC
- 17 Dec 2021, 11:29
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 14 Dec 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Dec 2021, 17:31
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 10 Dec 2021
- Transactions
- 1
- Transaction value
- +$36,365
- Accepted by SEC
- 13 Dec 2021, 13:05
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 07 Dec 2021
- Transactions
- 2
- Transaction value
- +$26,214
- Accepted by SEC
- 09 Dec 2021, 11:12
- Role
- Director
- Next action
- Open filing details
4
LA JOLLA PHARMACEUTICAL CO
- Report period
- 02 Dec 2021
- Transactions
- 18
- Transaction value
- +$91,990
- Accepted by SEC
- 06 Dec 2021, 20:01
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 01 Dec 2021
- Transactions
- 2
- Transaction value
- +$27,128
- Accepted by SEC
- 02 Dec 2021, 11:48
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 29 Nov 2021
- Transactions
- 2
- Transaction value
- +$27,157
- Accepted by SEC
- 01 Dec 2021, 12:15
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 18 Nov 2021
- Transactions
- 3
- Transaction value
- +$215,393
- Accepted by SEC
- 22 Nov 2021, 10:43
- Role
- Director
- Next action
- Open filing details
4
LA JOLLA PHARMACEUTICAL CO
- Report period
- 17 Nov 2021
- Transactions
- 1
- Transaction value
- +$31,725
- Accepted by SEC
- 19 Nov 2021, 16:05
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 28 Sep 2021
- Transactions
- 3
- Transaction value
- +$176,382
- Accepted by SEC
- 30 Sep 2021, 12:37
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 17 Aug 2021
- Transactions
- 3
- Transaction value
- +$115,181
- Accepted by SEC
- 19 Aug 2021, 20:12
- Role
- Director
- Next action
- Open filing details
4
LA JOLLA PHARMACEUTICAL CO
- Report period
- 24 May 2021
- Transactions
- 12
- Transaction value
- +$69,838
- Accepted by SEC
- 26 May 2021, 18:28
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 19 May 2021
- Transactions
- 1
- Transaction value
- +$7,905
- Accepted by SEC
- 20 May 2021, 17:44
- Role
- Director
- Next action
- Open filing details
4
SVRA
Savara Inc
- Report period
- 18 May 2021
- Transactions
- 1
- Transaction value
- +$81,100
- Accepted by SEC
- 18 May 2021, 17:36
- Role
- Director
- Next action
- Open filing details